



---

16:50-17:40 **Role and Current Status of Immunotherapy in Lung Cancer**

---

## **Mike Holmes**

MSD, Vice President and Head, Global Oncology Medical Affairs  
Specialty: Oncology Medical Affairs

### **[Recent Activities]**

- Vice President and Head, Global Oncology Medical Affairs at MSD
- 6.5 years at MSD
- 21 years in the pharmaceutical industry, focus on oncology medical affairs and clinical research
- 10 years in clinical practice in UK, oncological surgery

### **[Research Interests]**

- Immune Oncology Across a Broad Range of Tumor Types. PARP Inhibition (with AstraZeneca), VEGF Inhibition (with Eisai), Antibody drug Conjugates and BTKi Inhibition.